Skip to main content

Table 1 Patients’ characteristics and clinicopathological features

From: Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer

Age median (range), (y.o.) 50 (33–74)
Metastatic de-novo or recurrent, (n)
 Metastatic de-novo 10 (27.8%)
 Metastatic recurrent 26 (72.2%)
Subtype
 Luminal 29 (80.6%)
 Triple negative 7 (19.4%)
Number of previous chemotherapy regimens, (n)
 0 22 (61.1%)
 1 10 (27.8%)
 2 2 (5.6%)
3 2 (5.6%)
Previous endocrine therapy, (n) 26 (72.2%)
Metastatic sites, (n)
 Visceral 23 (63.9%)
 Non-visceral 13 (36.1%)
\